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Background
The ever-growing amount of new substances released to
the market and the limited predictability of current in
vitro test systems has led to an ample need for new sub-
stance testing solutions. Many drugs like troglitazone,
that had to be removed from the market due to drug
induced liver injury, show their toxic potential only after
chronic long term exposure. But for long-term multiple
dosing experiments, a controlled microenvironment is
pivotal, as even minor alterations in extracellular condi-
tions may greatly influence the cell physiology. Within
our research program, we focused on the generation of a
micro-engineered bioreactor, which can be dynamically
perfused by an on-chip pump and combines at least two
culture spaces for multi-organ applications. This circula-
tory systems better mimics the in vivo conditions of pri-
mary cell cultures and assures steadier, more quantifiable
extracellular signaling to the cells.
Materials and methods
Liver microtissues (aggregates of HepaRG+human hepatic
stellate cells) and skin biopsies were cultured in separate
inserts of a 96-well Transwell® unit (Corning), which were
hung inside the chip with the membrane fitting directly
over the circuit. The tissues were cultivated either air/
liquid interfaced (skin) or submerged in media (liver
equivalent) for a culture period of 28 days. Exposing the
tissues to troglitazone, the cultures were cultured for one
day in normal medium and were, subsequently, exposed
to 0 μM, 5 μM and 50 μM troglitazone, respectively for
further 6 days. Application of troglitazone was repeated at
12 h intervals simultaneously with the medium change. In
a further experiment co-cultures of liver and skin equiva-
lents were cultured in a fully vascularized chip. Therefore,
HDMECs isolated from human foreskin were seeded into
the microfluidic channel system using a syringe. After
even cell infusion inside the circuit the device was incu-
bated in 5% CO2 at 37°C under static conditions for 3 h to
allow the cells to attach to the channel walls. A frequency
of 0.476 Hz was applied for continuous dynamic opera-
tion, after 10 days of monoculture, skin and liver tissue
were added for co-cultivation for another 15 days.
Results
Co-cultures of human artificial liver microtissues and
skin biopsies have successfully proven the long-term
performance of the novel microfluidic multi-organ-chip
device. The metabolic activity of the co-culture analysed
in media supernatants reached a steady state at day 7 of
co-culture and stayed constant for the rest of the culture
period (Figure 1A). Furthermore, the co-cultures
revealed a dose-dependent response to a 6-day exposure
to the toxic substance troglitazone. Liver microtissues
showed sensitivity at different molecular levels. LDH
levels measured in the media supernatants increased sig-
nificantly with increasing troglitazone concentration
(Figure 1B). Furthermore, an induction of Cyp450 3A4
levels on RNA level were observed (Figure 1C). In addi-
tion, a robust procedure applying pulsatile shear stress
has been established to cover all fluid contact surfaces
of the system with a functional, tightly closed layer of
HDMECs and co-cultivation of liver, skin and endothe-
lial cells for 15 days was successful.
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Conclusion
A unique chip-based tissue culture platform has been
developed enabling the testing of drugs or chemicals on a
set of miniaturized human organs. This “human-on-a-
chip” platform is designed to generate high quality in vitro
data predictive of substance safety in humans. Tissue co-
cultures can be exposed to pharmaceutical substances at
regimens relevant to respective guidelines, currently used
for subsystemic substance testing in animals.
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Figure 1 Multi-tissue culture in the MOC device. (A) Liver and skin tissue performance over 28-day MOC co-culture. Metabolic activity of the
co-culture analysed in media supernatants. (B) LDH values (C) Real-time qPCR of the cytochrome P450 3A4. Statistical analysis was performed by
one-way analysis of variance (ANOVA), followed by post-hoc Dunnett’s pairwise multiple comparison test. * P < 0.05 versus control. Data are means
± SEM (n = 4).
Materne et al. BMC Proceedings 2013, 7(Suppl 6):P71
http://www.biomedcentral.com/1753-6561/7/S6/P71
Page 2 of 2
